Biodynamik Receives Grant From National Science Foundation
Lake Forest, CA – December 11, 2024 – Biodynamik Inc. is excited to announce its receipt of a prestigious grant from the National Science Foundation (NSF), a milestone achievement that underscores the company’s commitment to advancing groundbreaking research and innovation.
“NSF accelerates the translation of emerging technologies into transformative new products and services,” said Erwin Gianchandani, NSF Assistant Director for Technology, Innovation and Partnerships. “We take great pride in funding deep-technology startups and small businesses that will shape science and engineering results into meaningful solutions for today and tomorrow.”
All proposals submitted to the NSF SBIR/STTR program, also known as America’s Seed Fund powered by NSF, undergo a rigorous merit-based review process. Once a small business is awarded a Phase I grant, it becomes eligible to apply for Phase II funding and additional supplements totaling up to $2 million. To get started, startups or entrepreneurs submit a written Project Pitch to see if their technology idea could be a good fit for the program. To learn more about America’s Seed Fund powered by NSF, visit: https://seedfund.nsf.gov/
About the U.S. National Science Foundation’s Small Business Program
America’s Seed Fund powered by NSF awards more than $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $2 million to support research and development, helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the Small Business Innovation Research program. The NSF is an independent federal agency with a budget of about $9.5 billion that supports fundamental research and education across all fields of science and engineering.
About Biodynamik
Biodynamik, Inc. develops orthopedic external fixation systems. The XT3® System is FDA 510(k) cleared for fracture fixation, nonunion, transverse bone transport of the tibia, and the correction of bony or soft tissue defects and deformities in adult patients. Biodynamik is sponsoring the SMILE-TTT study (IDE G260049) of transverse tibial transport in patients with diabetic foot ulcers; this use is investigational.
